Biomedical or Dental Material
Pharma Ads Make Waves at Super Bowl 2025: Pfizer Wins Hearts, Hims & Hers Drives Engagement
Super Bowl 2025, pharmaceutical advertising, Pfizer, Hims & Hers, ad likeability, viewer engagement, healthcare marketing, cancer awareness, weight loss drugs
Hims & Hers Super Bowl Ad Sparks Controversy Over Weight Loss Drug Marketing
Hims & Hers, Super Bowl ad, weight loss drugs, FDA scrutiny, compounded GLP-1 drugs, pharmaceutical advertising, telehealth, consumer safety
Merck Suspends Gardasil Shipments to China, Lowers 2025 Revenue Forecast
Merck, Gardasil, China, revenue forecast, cancer vaccine, shipment suspension
Metsera and Maze Therapeutics Raise $415 Million in Successful Biotech IPOs
Biotech IPOs, Metsera, Maze Therapeutics, obesity treatment, kidney disease, NASDAQ listings, pharmaceutical funding
Sanofi Acquires Exclusive Rights to Develop and Commercialize Cytokinetics’ Aficamten in Greater China
Sanofi, Cytokinetics, Aficamten, Greater China, Hypertrophic Cardiomyopathy (HCM), Cardiac Myosin Inhibitor, Pharmaceutical Deal
Lonza Expands Gelatin Capsule Production in India and China Amid Plans to Exit Capsules Business
Lonza, Capsules & Health Ingredients, Gelatin Capsules, India, China, Expansion, Exit Strategy
FDA Confirms Tirzepatide Availability, Compounders Express Concerns, While Semaglutide Shortage Persists
FDA, tirzepatide, semaglutide, GLP-1 drug shortage, compounders, pharmaceutical availability
Keros Therapeutics Faces Major Setback as PAH Trial Dosing Suspended Over Safety Concerns
Keros Therapeutics, PAH trial, dosing suspension, safety concerns, pulmonary arterial hypertension, cibotercept (KER-012), Phase II TROPOS trial
Lonza Announces Strategic Shift to Focus on CDMO Business, Exits Capsules & Health Ingredients
Lonza, CDMO, Capsules & Health Ingredients, Restructure, One Lonza Strategy
Novo Nordisk Invests $409M in New Quality Control Lab in Denmark
Novo Nordisk, quality control lab, Denmark, pharmaceutical investment, biotechnology